Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck

The majority of patients with recurrent/metastatic squamous cell carcinoma of the head and neck (HNSCC) (R/M) do not benefit from anti-PD-1 therapy. Hypoxia induced immunosuppression may be a barrier to immunotherapy. Therefore, we examined the metabolic effect of anti-PD-1 therapy in a murine MEER...

Descripción completa

Detalles Bibliográficos
Autores principales: Zandberg, Dan P, Menk, Ashley V, Velez, Maria, Normolle, Daniel, DePeaux, Kristin, Liu, Angen, Ferris, Robert L, Delgoffe, Greg M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126285/
https://www.ncbi.nlm.nih.gov/pubmed/33986123
http://dx.doi.org/10.1136/jitc-2020-002088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126285/
https://www.ncbi.nlm.nih.gov/pubmed/33986123
http://dx.doi.org/10.1136/jitc-2020-002088

Ejemplares similares